Table 1 Charing cross hospital prognostic scoring system

From: Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects

Variable

0

1

2

6

Age (years)

⩽39

>39

  

Antecedent pregnancy (AP)

Mole

Abortion/unknown

Term

 

Interval between AP to treatment (months) hCG (IU l−1)

<4

4–6

7–12

>12

 

103–104

<103

104–105

>105

ABO blood group (female × male)

 

A × O

B × O or O

 
  

O × A

AB × A or O

 
  

O or A × unknown

  

Number of metastases

 

1–4

4–8

>8

Site of metastases

Lungs, vagina

Spleen, kidneys

Gastrointestinal tract, liver

Brain

Largest tumour mass

<3 cm

3–5 cm

>5 cm

 

Previous chemotherapy

  

Single drug

Two or more drugs

  1. hCG=human chorionic gonadotrophin; Charing Cross System – low risk: 0−5, intermediate risk: 6−9, high risk: >9. Sheffield modification – low risk: 0−7, high risk: >7.
Back to article page